Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice

T.L.M. ten Hagen, A.C.T.M. Vossen, W. van Vianen, G.J.M. Tibbe, H.F.J. Savelkoul, H. Heremans, I.A.J.M. Bakker-Woudenberg

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Administration of liposome-encapsulated immunomodulating agents muramyl tripeptide phosphatidyl ethanolamine (LE-MTPPE) or interferon-gamma (LE-IFN-gamma), or co-encapsulated MTPPE and IFN-gamma (LE-(MTPPE/IFN-gamma)) resulted in a dramatic increase of the nonspecific antimicrobial resistance in mice, as shown before. This kind of treatment is especially of use in immunocompromised hosts who are prone to severe infections. Application of these immunomodulators might protect these patients, e.g., transplant recipients, from opportunistic infections. However, accelerated rejection of the graft, resulting from augmentation of the antimicrobial defense in a nonspecific way, has to be avoided. In this study, the effect of treatment with LE-MT-PPE, LE-IFN-gamma, or LE-(MTPPE/IFN-gamma) on skin graft rejection in mice was investigated. It was found that prophylactic treatment of skin-grafted mice with immunomodulating formulations did not influence rejection of the graft. Moreover, in T cell-depleted mice, which showed a prolonged graft survival compared with immunocompetent recipients, the administration of immunomodulators did not change the survival time of the grafts compared with T cell-depleted mice that did not receive immunomodulators. The results clearly show that, in this experimental setting, application of the antimicrobial resistance-enhancing formulations (LE-MTPPE, LE-IFN-gamma, and LE-(MTPPE/IFN-gamma)) is allowed in graft-bearing recipients, without influencing graft survival.
Original languageEnglish
Pages (from-to)1211-1214
JournalTransplantation
Volume60
Issue number11
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Graft Rejection
Immunologic Factors
Liposomes
Graft Survival
Skin
Interferon-gamma
Ethanolamine
T-Lymphocytes
Opportunistic Infections
Immunocompromised Host
Therapeutics
Transplants
Infection

Cite this

ten Hagen, T. L. M., Vossen, A. C. T. M., van Vianen, W., Tibbe, G. J. M., Savelkoul, H. F. J., Heremans, H., & Bakker-Woudenberg, I. A. J. M. (1995). Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. Transplantation, 60(11), 1211-1214.
ten Hagen, T.L.M. ; Vossen, A.C.T.M. ; van Vianen, W. ; Tibbe, G.J.M. ; Savelkoul, H.F.J. ; Heremans, H. ; Bakker-Woudenberg, I.A.J.M. / Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. In: Transplantation. 1995 ; Vol. 60, No. 11. pp. 1211-1214.
@article{fb22212220634edb9086f68d8b513bd1,
title = "Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice",
abstract = "Administration of liposome-encapsulated immunomodulating agents muramyl tripeptide phosphatidyl ethanolamine (LE-MTPPE) or interferon-gamma (LE-IFN-gamma), or co-encapsulated MTPPE and IFN-gamma (LE-(MTPPE/IFN-gamma)) resulted in a dramatic increase of the nonspecific antimicrobial resistance in mice, as shown before. This kind of treatment is especially of use in immunocompromised hosts who are prone to severe infections. Application of these immunomodulators might protect these patients, e.g., transplant recipients, from opportunistic infections. However, accelerated rejection of the graft, resulting from augmentation of the antimicrobial defense in a nonspecific way, has to be avoided. In this study, the effect of treatment with LE-MT-PPE, LE-IFN-gamma, or LE-(MTPPE/IFN-gamma) on skin graft rejection in mice was investigated. It was found that prophylactic treatment of skin-grafted mice with immunomodulating formulations did not influence rejection of the graft. Moreover, in T cell-depleted mice, which showed a prolonged graft survival compared with immunocompetent recipients, the administration of immunomodulators did not change the survival time of the grafts compared with T cell-depleted mice that did not receive immunomodulators. The results clearly show that, in this experimental setting, application of the antimicrobial resistance-enhancing formulations (LE-MTPPE, LE-IFN-gamma, and LE-(MTPPE/IFN-gamma)) is allowed in graft-bearing recipients, without influencing graft survival.",
author = "{ten Hagen}, T.L.M. and A.C.T.M. Vossen and {van Vianen}, W. and G.J.M. Tibbe and H.F.J. Savelkoul and H. Heremans and I.A.J.M. Bakker-Woudenberg",
year = "1995",
language = "English",
volume = "60",
pages = "1211--1214",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott, Williams & Wilkins",
number = "11",

}

ten Hagen, TLM, Vossen, ACTM, van Vianen, W, Tibbe, GJM, Savelkoul, HFJ, Heremans, H & Bakker-Woudenberg, IAJM 1995, 'Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice' Transplantation, vol. 60, no. 11, pp. 1211-1214.

Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. / ten Hagen, T.L.M.; Vossen, A.C.T.M.; van Vianen, W.; Tibbe, G.J.M.; Savelkoul, H.F.J.; Heremans, H.; Bakker-Woudenberg, I.A.J.M.

In: Transplantation, Vol. 60, No. 11, 1995, p. 1211-1214.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice

AU - ten Hagen, T.L.M.

AU - Vossen, A.C.T.M.

AU - van Vianen, W.

AU - Tibbe, G.J.M.

AU - Savelkoul, H.F.J.

AU - Heremans, H.

AU - Bakker-Woudenberg, I.A.J.M.

PY - 1995

Y1 - 1995

N2 - Administration of liposome-encapsulated immunomodulating agents muramyl tripeptide phosphatidyl ethanolamine (LE-MTPPE) or interferon-gamma (LE-IFN-gamma), or co-encapsulated MTPPE and IFN-gamma (LE-(MTPPE/IFN-gamma)) resulted in a dramatic increase of the nonspecific antimicrobial resistance in mice, as shown before. This kind of treatment is especially of use in immunocompromised hosts who are prone to severe infections. Application of these immunomodulators might protect these patients, e.g., transplant recipients, from opportunistic infections. However, accelerated rejection of the graft, resulting from augmentation of the antimicrobial defense in a nonspecific way, has to be avoided. In this study, the effect of treatment with LE-MT-PPE, LE-IFN-gamma, or LE-(MTPPE/IFN-gamma) on skin graft rejection in mice was investigated. It was found that prophylactic treatment of skin-grafted mice with immunomodulating formulations did not influence rejection of the graft. Moreover, in T cell-depleted mice, which showed a prolonged graft survival compared with immunocompetent recipients, the administration of immunomodulators did not change the survival time of the grafts compared with T cell-depleted mice that did not receive immunomodulators. The results clearly show that, in this experimental setting, application of the antimicrobial resistance-enhancing formulations (LE-MTPPE, LE-IFN-gamma, and LE-(MTPPE/IFN-gamma)) is allowed in graft-bearing recipients, without influencing graft survival.

AB - Administration of liposome-encapsulated immunomodulating agents muramyl tripeptide phosphatidyl ethanolamine (LE-MTPPE) or interferon-gamma (LE-IFN-gamma), or co-encapsulated MTPPE and IFN-gamma (LE-(MTPPE/IFN-gamma)) resulted in a dramatic increase of the nonspecific antimicrobial resistance in mice, as shown before. This kind of treatment is especially of use in immunocompromised hosts who are prone to severe infections. Application of these immunomodulators might protect these patients, e.g., transplant recipients, from opportunistic infections. However, accelerated rejection of the graft, resulting from augmentation of the antimicrobial defense in a nonspecific way, has to be avoided. In this study, the effect of treatment with LE-MT-PPE, LE-IFN-gamma, or LE-(MTPPE/IFN-gamma) on skin graft rejection in mice was investigated. It was found that prophylactic treatment of skin-grafted mice with immunomodulating formulations did not influence rejection of the graft. Moreover, in T cell-depleted mice, which showed a prolonged graft survival compared with immunocompetent recipients, the administration of immunomodulators did not change the survival time of the grafts compared with T cell-depleted mice that did not receive immunomodulators. The results clearly show that, in this experimental setting, application of the antimicrobial resistance-enhancing formulations (LE-MTPPE, LE-IFN-gamma, and LE-(MTPPE/IFN-gamma)) is allowed in graft-bearing recipients, without influencing graft survival.

M3 - Article

VL - 60

SP - 1211

EP - 1214

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -